The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype
- PMID:18620730
- DOI: 10.1016/j.humpath.2008.03.004
The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype
Abstract
Gene expression studies have identified a basal phenotype of breast cancer; these are hormone receptor and HER2-negative cancers with poor prognosis. High levels of cyclin E and Skp2, and low levels of p27 have previously been individually associated with both basal-like breast cancer and a poor outcome after diagnosis. The goal of this study was to first confirm the prognostic value of these biomolecular markers using a breast cancer tissue microarray. Second, we also test the hypothesis that the combined phenotype of high cyclin E, low p27, and high Skp2 would be a strong predictor of outcome and would be closely associated with the basal phenotype of breast cancer. Our cohort consisted of 438 cases of breast cancer and the median follow-up was 15.4 years. The tissue microarray was constructed from archival tumor blocks and we used commercially available antibodies for biomarker immunostaining. Cyclin E was positive in 46% of cases, p27 was negative in 62%, and Skp2 was positive in 35%. We found cyclin E and Skp2 to be prognostic for breast cancer-specific survival in univariate analyses, but p27 was not prognostic. The strongest predictor of outcome was the combination of cyclin E positive and Skp2 positive (difference in survival of 19% at 10 years, P = .0009). This combination was present in 78 (27%) of 288 cases for which data on both biomarkers were available. This combination was also highly associated with young age at diagnosis, grade 3 tumors, ER-negative status, HER2-negative status, and the basal biomarkers epidermal growth factor receptor and cytokeratin 5/6. However, in a multivariate model including standard clinicopathologic variables, this combination was not found to have independent prognostic significance. In conclusion, the combination of high cyclin E and Skp2 expression predicts for poor prognosis in breast cancer in univariate analysis only, it is associated with high risk features, and it is associated with the basal phenotype.
Similar articles
- Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.Arnes JB, Brunet JS, Stefansson I, Bégin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD.Arnes JB, et al.Clin Cancer Res. 2005 Jun 1;11(11):4003-11. doi: 10.1158/1078-0432.CCR-04-2064.Clin Cancer Res. 2005.PMID:15930334
- Prognostic impact of Skp2 and p27 in human breast cancer.Traub F, Mengel M, Lück HJ, Kreipe HH, von Wasielewski R.Traub F, et al.Breast Cancer Res Treat. 2006 Sep;99(2):185-91. doi: 10.1007/s10549-006-9202-3. Epub 2006 Apr 25.Breast Cancer Res Treat. 2006.PMID:16636894
- Significance of skp2 expression in primary breast cancer.Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda TA, Mori M.Sonoda H, et al.Clin Cancer Res. 2006 Feb 15;12(4):1215-20. doi: 10.1158/1078-0432.CCR-05-1709.Clin Cancer Res. 2006.PMID:16489076
- E- and A-type cyclins as markers for cancer diagnosis and prognosis.Yasmeen A, Berdel WE, Serve H, Müller-Tidow C.Yasmeen A, et al.Expert Rev Mol Diagn. 2003 Sep;3(5):617-33. doi: 10.1586/14737159.3.5.617.Expert Rev Mol Diagn. 2003.PMID:14510182Review.
- Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer.Hershko DD.Hershko DD.Cancer. 2008 Apr 1;112(7):1415-24. doi: 10.1002/cncr.23317.Cancer. 2008.PMID:18260093Review.
Cited by
- Triple-negative breast cancer: are we making headway at least?Arnedos M, Bihan C, Delaloge S, Andre F.Arnedos M, et al.Ther Adv Med Oncol. 2012 Jul;4(4):195-210. doi: 10.1177/1758834012444711.Ther Adv Med Oncol. 2012.PMID:22754593Free PMC article.
- Morphological and pathological features of basal-like breast cancer.Botti G, Cantile M, Collina F, Cerrone M, Sarno S, Anniciello A, Di Bonito M.Botti G, et al.Transl Cancer Res. 2019 Oct;8(Suppl 5):S503-S509. doi: 10.21037/tcr.2019.06.50.Transl Cancer Res. 2019.PMID:35117128Free PMC article.Review.
- Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.Aziz D, Portman N, Fernandez KJ, Lee C, Alexandrou S, Llop-Guevara A, Phan Z, Yong A, Wilkinson A, Sergio CM, Ferraro D, Etemadmoghadam D, Bowtell DD; kConFab Investigators; Serra V, Waring P, Lim E, Caldon CE.Aziz D, et al.NPJ Breast Cancer. 2021 Aug 31;7(1):111. doi: 10.1038/s41523-021-00312-x.NPJ Breast Cancer. 2021.PMID:34465787Free PMC article.
- Triple-negative breast cancer: disease entity or title of convenience?Carey L, Winer E, Viale G, Cameron D, Gianni L.Carey L, et al.Nat Rev Clin Oncol. 2010 Dec;7(12):683-92. doi: 10.1038/nrclinonc.2010.154. Epub 2010 Sep 28.Nat Rev Clin Oncol. 2010.PMID:20877296Review.
- Biomarkers for Basal-like Breast Cancer.Choo JR, Nielsen TO.Choo JR, et al.Cancers (Basel). 2010 May 28;2(2):1040-65. doi: 10.3390/cancers2021040.Cancers (Basel). 2010.PMID:24281106Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous